{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27(6)"],"submitter":["Kingo K"],"pubmed_abstract":["Background
The efficacy and safety of secukinumab up to week 52 in children and adolescents with moderate-to-severe chronic plaque psoriasis have been demonstrated previously (NCT03668613). Herein, we report the long-term efficacy, safety, and tolerability of secukinumab over a period of up to 208 weeks.Methods
In this randomized open-label trial, patients (6 to < 18 years) were randomized 1:1 to receive low-dose (LD; N = 42) or high-dose (HD; N = 42) secukinumab stratified by weight (< 25 kg, 25 to < 50 kg, or ≥ 50 kg) and disease severity (moderate or severe). Patients weighing < 25 kg received 75 mg secukinumab (both LD and HD); 25 to < 50 kg received 75 mg (LD) or 150 mg (HD) secukinumab; and ≥ 50 kg received 150 mg (LD) or 300 mg (HD) secukinumab. The study assessed Ps"],"journal":["Paediatric drugs"],"pagination":["749-759"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12534278"],"repository":["biostudies-literature"],"pubmed_title":["Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial."],"pmcid":["PMC12534278"],"pubmed_authors":["Bartonova J","Papanastasiou P","Ballona R","Magnolo N","Ravichandran S","O'Doherty C","Beissert S","Bansal A","Fan H","Villa AV","Lazareva S","Kingo K","Martin R"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial.","description":"Background
The efficacy and safety of secukinumab up to week 52 in children and adolescents with moderate-to-severe chronic plaque psoriasis have been demonstrated previously (NCT03668613). Herein, we report the long-term efficacy, safety, and tolerability of secukinumab over a period of up to 208 weeks.Methods
In this randomized open-label trial, patients (6 to < 18 years) were randomized 1:1 to receive low-dose (LD; N = 42) or high-dose (HD; N = 42) secukinumab stratified by weight (< 25 kg, 25 to < 50 kg, or ≥ 50 kg) and disease severity (moderate or severe). Patients weighing < 25 kg received 75 mg secukinumab (both LD and HD); 25 to < 50 kg received 75 mg (LD) or 150 mg (HD) secukinumab; and ≥ 50 kg received 150 mg (LD) or 300 mg (HD) secukinumab. The study assessed Ps","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-07-15T11:55:55.26Z","creation":"2026-07-04T03:12:11.512Z"},"accession":"S-EPMC12534278","cross_references":{"pubmed":["40874954"],"doi":["10.1007/s40272-025-00715-4"]}}